πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,022 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11285139

Treatment of CNS conditions

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11279713

Heterocyclic compound and use thereof

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11274101

Heterocyclic compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11273182

Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11268154

Methods for the identification, evaluation and treatment of patients having multiple myelo

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11254731

Viral vectors encoding recombinant FVIII variants with increased expression for gene thera

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11242380

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11236099

Heterocyclic compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11230545

Heterocyclic compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11230541

Heterocyclic compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11202776

Treatment of gastroparesis with triazaspiro[4.5]decanone

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11197916

Lyophilized recombinant VWF formulations

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11191837

Recombinant VWF formulations

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11191818

Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sick

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11191813

Lyophilized recombinant VWF formulations

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11186565

Aromatic compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11185575

Subcutaneous administration of ADAMTS13

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11174301

Peptide compound

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11174272

1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative di

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11173161

4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11173147

Prophylactic or therapeutic agent for delirium

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11168083

Inhibitors of Plasma Kallikrein and uses thereof

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11160850

Compositions of human prothrombin and activated factor X for improving hemostasis in the t

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11156612

Methods of determining levels of cleaved and/or intact kininogen

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted